CB-5339
- Generic Name
- CB-5339
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia, in RelapseMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Cleave Therapeutics, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04402541
- Locations
- 🇺🇸
MD Anderson Cancer Cancer, Houston, Texas, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸KU Clinical Research Center, Fairway, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath